Sugi Predict

Sugi Predict / Compounds / SCHEMBL1245089

SCHEMBL1245089

SCHEMBL1245089

Cc1cc(O)c(C(C)C)cc1C(C)C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.65
▸ TRPA1 O75762 2/20 0.52
▸ CHRM1 P11229 1/20 0.52
▸ SLC6A2 P23975 1/20 0.52
▸ ADRA1A P35348 1/20 0.52
▸ HTR2B P41595 1/20 0.52
▸ PKM P14618 3/20 0.49
▸ CYP1A2 P05177 4/20 0.47
▸ CYP2D6 P10635 3/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ MAPT P10636 5/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ CYP3A4 P08684 3/20 0.45
▸ CYP2C19 P33261 3/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ ALOX15 P16050 2/20 0.45
▸ HIF1A Q16665 2/20 0.45
▸ THRB P10828 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ GAA P10253 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30411784 1.00 LMNA (0.65) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL3824782 0.91 LMNA (0.61) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL1487434 0.90 LMNA (0.59) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL5526048 0.89 LMNA (0.53) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL29872559 0.87 LMNA (0.68) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL15012642 0.87 LMNA (0.56) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL214157 0.87 LMNA (0.68) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL9556365 0.85 LMNA (0.65) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL69082 0.85 LMNA (0.65) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL30213582 0.85 LMNA (0.65) LMNATRPA1CHRM1SLC6A2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119707641-A High-value utilization process for liquid-phase byproducts of thymol synthesis alkylation workshop 安徽海华科技集团有限公司 2025-03-28 — — CN claimed
CN-116020157-A Equipment for purifying p-thymol by melt crystallization and application method thereof 安徽海华科技集团有限公司 2023-04-28 — — CN claimed
CN-109792990-A Plants essential oil inhibits the application of mould in air in museum 广西民族博物馆 2019-05-24 — — CN claimed
CN-109400448-A A method of producing the aromachemicals based on alkyl phenol by enzymolysis xylogen 定州市荣鼎水环境生化技术有限公司 2019-03-01 — — CN claimed
US-4065362-A Purification of organic isocyanates SUMITOMO BAYER URETHANE CO., LTD. (JA) 1977-12-27 — — US claimed
CN-119707638-A Thymol byproduct transalkylation process 安徽海华科技集团有限公司 2025-03-28 — — CN disclosed
CN-119707638-A Thymol byproduct transalkylation process 安徽海华科技集团有限公司 2025-03-28 — — CN disclosed
CN-119707641-A High-value utilization process for liquid-phase byproducts of thymol synthesis alkylation workshop 安徽海华科技集团有限公司 2025-03-28 — — CN disclosed
CN-119709517-A Bacillus bailii CK3-5 as tobacco source, amylase and application thereof 内蒙古昆明卷烟有限责任公司 2025-03-28 — — CN disclosed
CN-119707641-A High-value utilization process for liquid-phase byproducts of thymol synthesis alkylation workshop 安徽海华科技集团有限公司 2025-03-28 — — CN disclosed
CN-118812313-A Method for preparing aviation fuel naphthene component by using guaiacol 山东理工大学 2024-10-22 — — CN disclosed
CN-219302016-U Sampling device for purifying p-thymol by melting crystallization 安徽海华科技集团有限公司 2023-07-04 — — CN disclosed
WO-2008017484-A1 NOVEL AGENTS FOR THE TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION DSM IP ASSETS B.V. (NL) 2008-02-14 — — WO disclosed
WO-2006074401-A1 ALKYLATION OF HYDROXYARENES WITH OLEFINS, ALCOHOLS AND ETHERS IN IONIC LIQUIDS SI GROUP, INC. (US) 2006-07-13 — — WO disclosed
US-20030100802-A1 Process for preparing 3,3',5,5',6,6'-hexaalkyl-2,2'-biphenols,3,3',4,4',5,5'-hexaalkyl-2,2'-biphenols and 3,3',4,4',5,5',6,6'-octaalkyl-2,2'-biphenols SHAPIRO RAFAEL (US) 2003-05-29 — — US disclosed
US-4469901-A PREFERENTIAL COMPLEXING KOPPERS COMPANY, INC. (US) 1984-09-04 — — US disclosed
US-4429169-A PREFERENTIAL COMPLEXING WITH METAL HALIDE KOPPERS COMPANY, INC. (US) 1984-01-31 — — US disclosed
US-4086283-A FROM M-CRESOL AND PROPYLENE WITH ALUMINA CATALYST AND AMMONIA, HYDRAZINE OR AMINE CATALYSTS BAYER AKTIENGESELLSCHAFT (DT) 1978-04-25 — — US disclosed
US-4065362-A Purification of organic isocyanates SUMITOMO BAYER URETHANE CO., LTD. (JA) 1977-12-27 — — US disclosed
US-3968173-A ALUMINUM SILICATE CATALYST BAYER AKTIENGESELLSCHAFT (DT) 1976-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100802-A1 Process for preparing 3,3',5,5',6,6'-hexaalkyl-2,2'-biphenols,3,3',4,4',5,5'-hexaalkyl-2,2'-biphenols and 3,3',4,4',5,5',6,6'-octaalkyl-2,2'-biphenols CYP4B1, UGT1A4, CYP4X1 LMNA 2946/4885TRPA1 2657/4885CHRM1 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.